Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $13.6 million.

  • Protalix BioTherapeutics' Cash & Equivalents fell 5020.98% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 5020.98%. This contributed to the annual value of $19.8 million for FY2024, which is 1639.16% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Cash & Equivalents stood at $13.6 million, which was down 5020.98% from $17.9 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Cash & Equivalents registered a high of $48.2 million during Q2 2023, and its lowest value of $10.6 million during Q3 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $19.8 million (2021), whereas its average is $22.9 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Cash & Equivalents surged by 59960.77% in 2021 and then crashed by 6313.09% in 2022.
  • Protalix BioTherapeutics' Cash & Equivalents (Quarter) stood at $39.0 million in 2021, then tumbled by 56.11% to $17.1 million in 2022, then soared by 38.12% to $23.6 million in 2023, then dropped by 16.39% to $19.8 million in 2024, then plummeted by 30.94% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $17.9 million for Q2 2025, and $19.5 million during Q1 2025.